EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms—A randomized controlled trial

Hao Xiang Chen iD, Shih-Hsin Chang iD, Der-Yuan Chen iD, Joung-Liang Lan iD, Kai-Jieh Yeo iD, Po-Hao Huang iD, Chung-Ming Huang iD, Chi-Ping Huang iD, Eric Chieh-Lung Chou iD, Po-Chang Wu iD

LUTS: Lower Urinary Tract Symptoms · 2023

DOI: 10.1111/luts.12481 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, 2023. Verfasst von Hao Xiang Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, China Medical University Hospital, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Sjogren's Syndrome, Urological Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Clinical Trial Center, China Medical University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study investigates the efficacy and adverse events of beta‐3 agonists and antimuscarinic agents for managing overactive bladder syndrome in Sjogren syndrome.

Methods

Sjogren's syndrome patients with an Overactive Bladder Symptom Score (OABSS) >5 were enrolled and were randomly assigned to mirabegron 50 mg/day or solifenacin 5 mg/day. Patients were evaluated on the recruitment day and reassessed at Week 1, 2, 4, and 12. The study's primary endpoint was to have a significant change in OABSS at Week 12. The secondary endpoint was the adverse event and crossover rate.

Results

A total of 41 patients were included in the final analysis, with 24 in the mirabegron group and 17 in the solifenacin group. The study's primary outcome was a change of the OABSS at Week 12. We found that both mirabegron and solifenacin significantly reduce patients' OABSS after 12 weeks of treatment. The evolution of the OABSS was −3.08 for mirabegron and −3.71 for solifenacin ( p = .56). Six out of 17 patients from the solifenacin group crossed over to the mirabegron arm due to severe dry mouth or constipation, while none from the mirabegron arm crossed over to the solifenacin group. Sjogren's syndrome‐related pain was also improved in the mirabegron group (4.96–1.67, p = .008) compared to the solifenacin group (4.39–3.4, p = .49).

Conclusions

Our study showed that mirabegron is equally effective as solifenacin in treating Sjogren's syndrome patients with overactive bladder. Mirabegron is superior to solifenacin in terms of treatment‐related adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder, OveractiveSjogren's SyndromeUrological AgentsHumansSolifenacin SuccinateTreatment OutcomeDrug Therapy, CombinationAcetanilidesMuscarinic AntagonistsThiazoles

Stichwörter der Autor:innen

Sjogren's syndromemirabegronoveractive bladdersolifenacin

Substanzen

Solifenacin SuccinateAcetanilidesMuscarinic AntagonistsUrological AgentsmirabegronThiazoles

Autor:innen und Institutionen

  • Department of Urology, China Medical University Hospital, China Medical University, Taichung, Taiwan.
  • Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
  • Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
  • Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan.
  • School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
  • Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan.

ORCID-Profile: Hao Xiang Chen, Shih-Hsin Chang, Der-Yuan Chen, Joung-Liang Lan, Kai-Jieh Yeo, Po-Hao Huang, Chung-Ming Huang, Chi-Ping Huang, Eric Chieh-Lung Chou, Po-Chang Wu

Förderung

  • Clinical Trial Center, China Medical University Hospital

Zitieren

APA

Chen, H. X., Chang, S. H., Chen, D. Y., Lan, J. L., Yeo, K. J., Huang, P. H., Huang, C. M., Huang, C. P., Chou, E. C., & Wu, P. C. (2023). Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms—A randomized controlled trial. LUTS: Lower Urinary Tract Symptoms. https://doi.org/10.1111/luts.12481

Vancouver

Chen HX, Chang SH, Chen DY, Lan JL, Yeo KJ, Huang PH, et al. Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms—A randomized controlled trial. LUTS: Lower Urinary Tract Symptoms. 2023. doi:10.1111/luts.12481

BibTeX
@article{Chen2023,
  author = {Chen, Hao Xiang and Chang, Shih-Hsin and Chen, Der-Yuan and Lan, Joung-Liang and Yeo, Kai-Jieh and Huang, Po-Hao and Huang, Chung-Ming and Huang, Chi-Ping and Chou, Eric Chieh-Lung and Wu, Po-Chang},
  title = {Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms—A randomized controlled trial},
  journal = {LUTS: Lower Urinary Tract Symptoms},
  year = {2023},
  doi = {10.1111/luts.12481}
}
Kostenlos starten →